ATNM actiniumpharma.com: Rentabilitas operasi

ATNM (Actinium Pharmaceuticals) - tandha merek perusahaan

Actinium Pharmaceuticals (ATNM) seeks to commercialize leukemia radiotherapy, yet the lack of stable cash flow creates financial pressure. The operating margin helps resolve this dissonance, while 26.10 determines a fresh valuation metric. Fundamental stability is provided by leadership in creating radioisotope conjugates and a robust patent shield, which forms a significant barrier to entry for third-party players.

ATNM: Rentabilitas kegiatan operasi Actinium Pharma 04.07.2022 - 20.11.2026

Rincian analitis perusahaan Actinium Pharmaceuticals

- rega saham lan konsensus proyeksi valuasi:
- data kapitalisasi saham perusahaan:
Pambiji fundamental perusahaan:ATNM, Actinium Pharmaceuticals, Inc.
Barang utama actiniumpharma.com

The stability of Actinium Pharmaceuticals (ATNM) currently depends on the efficiency of managing clinical trial costs in the absence of revenue. This indicator reflects the share of operating profit before taxes and interest, allowing investors to assess operating leverage and the rate of cost growth, which is clearly confirmed by the operating margin trend when analyzing business scaling.